Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: Relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome

American Journal of Tropical Medicine and Hygiene

Volumn 67, Issue 3, 2002, Pages 225-229

  Khalil, Insaf ^a   Alifrangis, Michael ^a   Rønn, Anita M ^a   Gabar, Haythem A ^a   Jelinek, Tomas ^a   Satti, Gwiria M H ^a   Bygbjerg, Ib C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; SULFADOXINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CODON; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0036748522     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.67.225     Document Type: Article

References (27)

1. Watkins WM, Mberu EK, Winstanley PA, Plowe CV, 1997. The efficacy of antimalarial combinations in Africa: a predictive model based on pharmacokinetic and pharmacodynamic analysis. Parasitol Today 13: 459-464,
2. Bloland PB, Lackritz EM, Kezembe PN, Were JB, Campbell CC, 1993. Beyond chloroquine: implication of drug resistance for evaluating malaria therapy, efficacy and treatment policy in Africa. J Infect Dis 167: 932-937.
3. Watkins WM, Mosobo M, 1993. Treatment of falciparum malaria with pyrimethamine/sulfadoxine: selection pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87: 75-78.
4. Foote S, Galatis P, Cowman A, 1990. Amino acids in dihydrofolate reductase gene of Plasmodium falciparum involved in cycloguanil differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci U S A 87: 3014-3017.
5. Triglia T, Cowman AF, 1994. Primary structure and expression of the dihydropteroate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 91: 13994-13999.
6. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC. Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carte D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dhfr and dhps and epidemiologic patterns of PYR/SDX use and resistance. J Infect Dis 176: 1590-1596.
7. Wang P, Lee C-S, Bayoumi R., Djimde A, Doumbo O, Swedberg, G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PFG, Hyde JE, 1997. Resistance to antifolate in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origin. Mol Biochem Parasitol 89: 161-177.
8. Wang P, Read M, Sims PFG, Hyde JE, 1997. Sulfadoxine resistance in human malaria parasite Plasmodium falciparum is determined by mutations in the dihydropteroate synthase gene and additional factor associated with folate utilization. Mol Microbiol 23: 979-986.
9. Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, Cortese JF, Plowe CV, 1998. Molecular surveillance of antifolate resistant malaria. Lancet 351: 1629-1630.
10. Wang P, Brobey RK, Horii T, Sims PFG, Hyde JE, 1999. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol 32: 1254-1262.
11. World Health Organization, 1973. Chemotherapy of malaria and resistance to antimalarial drugs. WHO Technical Report series No. 529. Geneva: WHO.
12. World Health Organization, 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO/MAL/96.1077. Geneva: WHO.
13. Ausubel F, Brent R, Kingston R, Moore D, Seidman J, Smith J, Struhl K, 1997. Short Protocols in Molecular Biology, New York: Welly & Sons Inc, 2-4.
14. Taylor A, 1997. Titration of heparinase for the removal of the PCR inhibitory of heparin in DNA samples. Mol Ecol 6: 383-385.
15. Duraisingh MT, Curtis J, Warhurst DC, 1998. Plasmodium falciparum: detection of polymorphism in the dihydrofolate reductase and dihydropteroate synthase genes by PCR and restriction digestion. Exp Parasitol 89: 1-8.
16. Barker RH Jr, Banchongaksorn T, Courval JM, Suwonkerd W, Rimwungtragoon K, Wirth DF, 1992. A simple method to detect P. falciparum directly from blood samples using the polymerase chain reaction. Am J Trop Med Hyg 46: 416-426.
17. Bergqvist Y, Hjelm E, Rombo L, 1987. Sulfadoxine assay using capillary blood samples dried on filter paper suitable for monitoring of drug concentrations in the field, Ther: Drug Monit 9: 203-207.
18. Ibrahim ME, EL Kariem FA, EL Hassan IM, Mubark H, 1991. A case of Plasmodium falciparum sensitive to chloroquine but resistant to PYR/SDX in Sinnar/Sudan. Trans R Soc Trop Med Hyg 85: 446.
19. Brobey RK, Sano G, Itoh F, Aso K, Kimura M, Mitamura T, 1996. Recombinant Plasmodium falciparum dihydrofolate reductase based on in vitro screen for antifolate antimalarials. Mol Biochem Parasitol 81: 225-237.
20. Wu Y, Kirkman LA, Wellems TE, 1996. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci U S A 93: 1130-1134.
21. Jelinek T, Rønn AM, Curtis J, Duraisingh MT, Lemnge MM, Bygbjerg IC, Warhurst DC, 1997. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum isolates from Tanzania without evidence of an association to clinical pyrimethamine/sulfadoxine resistance. Trop Med Int Health 2: 1025-1027.
22. Rallon N, Osorio L, Giraldo L, 1999. Lack of an association between the Asn 108 mutation in the dihydrofolate reductase gene and in vivo resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum. Am J Trop Med Hyg 61: 245-248.
23. Nzila-Mounda, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, 2000.Towards an understanding of the mechanism of pyrimethamine/sulfadoxine resistance in P. falciparum: genotyping of dhfr and dhps of Kenyan parasites. Antimicrob Agent Chemother 44: 991-996.
24. Jelinek T, Kilian A, Kabagambe G, Von Sonnenburg F, 1999. P. falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation to polymorphisms in the dihydrofolate reductase (dhfr) and dihydropetroate synthase (dhps) genes. Am J Trop Med Hyg 61: 463-466.
25. Mutabingwa T, Nzila A, Mberu E, Naduati E, Winstanley PA, Hills E, Watkins WM, 2001. Chlorproguanil-dapsone for treatment of drug resistant falciparum malaria in Tanzania. Lancet 358: 1218-1223.
26. Omar SA, Adagu IS, Warhurst DC, 2001. Can pretreatment screening for dhps and dhfr mutations in P. falciparum infections be used to predict sulfadoxine/pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95: 315-319.
27. Wellems TE, Plowe CV, 2001. Chloroquine resistant malaria. J Infect Dis 184: 770-776.